Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Jemekk Hedge Fund Gerard Ferguson & Rick Ummat | “Extendicare Inc. (EXE) is a Canadian senior care company headquartered in Markham, Ontario, operating long-term care homes, home health care (ParaMed), and managed/group purchasing services (SGP) across Canada — a network of 99 LTC homes, ~13.5 million home care hours delivered annually, and purchasing services covering ~152,000 beds. Canada's 85+ population is growing ~4% annually through 2051, giving Extendicare a multi-decade, near-guaranteed volume driver across its care segments. Home health ADV grew 32.7% y/y, with segment revenue up $47mm to $205mm and adjusted NOI margin expanding 300bps to 13.3% — growth with operating leverage, not margin dilution. Management has actively consolidated the space via the $570mm CBI Home Health acquisition plus Closing the Gap and nine Class C LTC homes. Home health now contributes 41.3% of adjusted NOI, LTC 44.1%, and managed services 14.7% — spreading reimbursement/regulatory risk across three streams while preserving the government-backed defensiveness investors value. Q1 2026 adjusted EBITDA rose 52.2% y/y to $44.2M; net income rose 171% to $40.7M. The balance sheet was reset with a $450mm senior notes issuance and a 5% dividend hike. Insiders have been net buyers, usually a bullish signal. We like Extendicare for the above reasons and add that its evolution from a single-segment LTC operator into a diversified national care platform gives it multiple growth levers while retaining defensive, government-backed cash flows. The key risk to watch is labour — a current province-wide rally over staffing and wages could pressure costs. Still, with revenue forecast to grow 13% annually (vs. 10% for the sector) and in the center of a secular growth theme, we think the re-rating from sleepy dividend payer to compounding growth and income story has further to go.” | NEUTRAL | Q2 2026 Jul 11, 2026 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
